Methicillin-susceptible and Methicillin-resistant Staphylococcus aureus Bacteremia: Nationwide Estimates of 30-Day Readmission, In-hospital Mortality, Length of Stay, and Cost in the United States
- 11 February 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 69 (12), 2112-2118
- https://doi.org/10.1093/cid/ciz123
Abstract
Background. Information on outcomes of methicillin-susceptible and -resistant Staphylococcus aureus (MSSA and MRSA, respectively) bacteremia, particularly readmission, is scarce and requires further research to inform optimal patient care. Methods. We performed a retrospective analysis using the 2014 Nationwide Readmissions Database, capturing 49.3% of US hospitalizations. We identified MSSA and MRSA bacteremia using International Classification of Diseases, Ninth Revision, Clinical Modification among patients aged >= 18 years. Thirty-day readmission, mortality, length of stay, and costs were assessed using Cox proportional hazards regression, logistic regression, Poisson regression, and generalized linear model with gamma distribution and log link, respectively. Results. Of 92089 (standard error [SE], 1905) patients with S. aureus bacteremia, 48.5% (SE, 0.4%) had MRSA bacteremia. Thirty-day readmission rate was 22% (SE, 0.3) overall with no difference between MRSA and MSSA, but MRSA bacteremia had more readmission for bacteremia recurrence (hazard ratio, 1.17 [95% confidence interval {CI}, 1.02-1.34]), higher in-hospital mortality (odds ratio, 1.15 [95% CI, 1.07-1.23]), and longer hospitalization (incidence rate ratio, 1.09 [95% CI, 1.06-1.11]). Readmission with bacteremia recurrence was particularly more common among patients with endocarditis, immunocompromising comorbidities, and drug abuse. The cost of readmission was $12425 (SE, $174) per case overall, and $19186 (SE, $623) in those with bacteremia recurrence. Conclusions. Thirty-day readmission after S. aureus bacteremia is common and costly. MRSA bacteremia is associated with readmission for bacteremia recurrence, increased mortality, and longer hospitalization. Efforts should continue to optimize patient care, particularly for those with risk factors, to decrease readmission and associated morbidity and mortality in patients with S. aureus bacteremia.Keywords
This publication has 41 references indexed in Scilit:
- Predictors of Mortality in Staphylococcus aureus BacteremiaClinical Microbiology Reviews, 2012
- Regression models for analyzing costs and their determinants in health care: an introductory reviewInternational Journal for Quality in Health Care, 2011
- Proportion of hospital readmissions deemed avoidable: a systematic reviewCMAJ : Canadian Medical Association Journal, 2011
- Mortality associated with in-hospital bacteraemia caused by Staphylococcus aureus: a multistate analysis with follow-up beyond hospital dischargeJournal of Antimicrobial Chemotherapy, 2010
- The Value of Infectious Diseases Consultation in Staphylococcus aureus BacteremiaAmerican Journal Of Medicine, 2010
- Temporal Trends in the Incidence ofStaphylococcus aureusBacteremia in Olmsted County, Minnesota, 1998 to 2005: A Population‐Based StudyClinical Infectious Diseases, 2009
- Mortality of S. aureus bacteremia and infectious diseases specialist consultation – A study of 521 patients in GermanyJournal of Infection, 2009
- Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort studyBMJ, 2006
- Comparison of Mortality Associated with Methicillin‐Resistant and Methicillin‐SusceptibleStaphylococcus aureusBacteremia: A Meta‐analysisClinical Infectious Diseases, 2003
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987